What does Scribe Therapeutics Inc. do?
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a…
What is Scribe Therapeutics Inc.'s P/E and P/B ratio?
Scribe Therapeutics Inc. has a P/E ratio of -4.7 and a P/B ratio of -2.06.
What is Scribe Therapeutics Inc.'s debt-to-equity ratio?
Scribe Therapeutics Inc. has a debt-to-equity ratio of -0.29.
How much does Scribe Therapeutics Inc. owe compared with what it owns?
Scribe Therapeutics Inc. owes $3.85 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Scribe Therapeutics Inc.'s Positivity rank?
Scribe Therapeutics Inc. is ranked #6,406 of 6,774 companies globally and #3,670 of 4,000 in United States on PositoAI, with a Positivity Score of -18,871.
Does Scribe Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Scribe Therapeutics Inc..
Where can I read the latest news about Scribe Therapeutics Inc.?
Recent headlines about Scribe Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Scribe Therapeutics Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Scribe Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.